Monk, Bradley JBradley JMonkToita, TakafumiTakafumiToitaWu, XiaohuaXiaohuaWuVázquez Limón, Juan CJuan CVázquez LimónTarnawski, RafalRafalTarnawskiMandai, MasakiMasakiMandaiShapira-Frommer, RonnieRonnieShapira-FrommerMahantshetty, UmeshUmeshMahantshettyDel Pilar Estevez-Diz, MariaMariaDel Pilar Estevez-DizZhou, QiQiZhouLimaye, SewantiSewantiLimayeGodinez, Francisco J RamirezFrancisco J RamirezGodinezOppermann Kussler, ChristinaChristinaOppermann KusslerVarga, SzilviaSzilviaVargaValdiviezo, NataliaNataliaValdiviezoAoki, DaisukeDaisukeAokiLeiva, ManuelManuelLeivaLee, Jung-YunJung-YunLeeSulay, RaymondRaymondSulayKreynina, YuliaYuliaKreyninaWEN-FANG CHENGRey, FelipeFelipeReyRong, YiYiRongKe, GuihaoGuihaoKeWildsmith, SophieSophieWildsmithLloyd, AndrewAndrewLloydDry, HannahHannahDryTablante Nunes, AnaAnaTablante NunesMayadev, JyotiJyotiMayadev2024-02-212024-02-212023-1214702045https://scholars.lib.ntu.edu.tw/handle/123456789/639833Concurrent chemoradiotherapy has been the standard of care for locally advanced cervical cancer for over 20 years; however, 30-40% of treated patients have recurrence or progression within 5 years. Immune checkpoint inhibition has improved outcomes for patients with PD-L1 positive metastatic or recurrent cervical cancer. We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer.en[SDGs]SDG3journal article10.1016/S1470-2045(23)00479-5380399912-s2.0-85178132630https://api.elsevier.com/content/abstract/scopus_id/85178132630